KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Asset Writedowns and Impairment (2020 - 2023)

Novartis Ag's Asset Writedowns and Impairment history spans 6 years, with the latest figure at -$940.0 million for Q2 2023.

  • On a quarterly basis, Asset Writedowns and Impairment fell 252.06% to -$940.0 million in Q2 2023 year-over-year; TTM through Jun 2023 was -$940.0 million, a 252.06% decrease, with the full-year FY2009 number at -$26.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment hit -$940.0 million in Q2 2023 for Novartis Ag, down from -$267.0 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for NVS hit a ceiling of -$267.0 million in Q2 2022 and a floor of -$940.0 million in Q2 2023.
  • Historically, Asset Writedowns and Impairment has averaged -$511.8 million across 4 years, with a median of -$420.0 million in 2020.
  • Biggest five-year swings in Asset Writedowns and Impairment: skyrocketed 47.55% in 2021 and later crashed 252.06% in 2023.
  • Tracing NVS's Asset Writedowns and Impairment over 4 years: stood at -$551.0 million in 2020, then surged by 47.55% to -$289.0 million in 2021, then increased by 7.61% to -$267.0 million in 2022, then crashed by 252.06% to -$940.0 million in 2023.
  • Business Quant data shows Asset Writedowns and Impairment for NVS at -$940.0 million in Q2 2023, -$267.0 million in Q2 2022, and -$289.0 million in Q2 2021.